Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

PATHWAY HEALTHCARE ALABAMA LLC

NPI: 1053855122 · BIRMINGHAM, AL 35235 · Rural Health Clinic/Center · NPI assigned 12/08/2016

$874K
Total Medicaid Paid
52,592
Total Claims
29,254
Beneficiaries
16
Codes Billed
2019-03
First Month
2024-11
Last Month

Provider Details

Authorized OfficialROX, RITA (REVENUE CYCLE MANAGER)
Parent OrganizationPATHWAY HEALTHCARE ALABAMA LLC
NPI Enumeration Date12/08/2016

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2019 12,650 $82K
2020 12,643 $126K
2021 9,692 $153K
2022 9,522 $237K
2023 6,080 $217K
2024 2,005 $60K

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
99214 Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity 17,233 9,505 $473K
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed 4,780 3,403 $281K
80305 17,562 9,722 $73K
99213 Office or other outpatient visit for the evaluation and management of an established patient, low complexity 1,234 665 $21K
99205 Prolong outpt/office vis 296 166 $15K
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 93 89 $5K
90833 Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) 216 149 $3K
99484 1,652 1,204 $2K
81025 1,063 490 $1K
90791 Psychiatric diagnostic evaluation 17 12 $1K
99406 6,740 2,854 $239.08
36415 Collection of venous blood by venipuncture 102 73 $102.00
G0444 Annual depression screening, 5 to 15 minutes 194 136 $0.00
G8431 Screening for depression is documented as being positive and a follow-up plan is documented 932 346 $0.00
G2086 Office-based treatment for opioid use disorder, including development of the treatment plan, care coordination, individual therapy and group therapy and counseling; at least 70 minutes in the first calendar month 29 25 $0.00
G2087 Office-based treatment for opioid use disorder, including care coordination, individual therapy and group therapy and counseling; at least 60 minutes in a subsequent calendar month 449 415 $0.00